Metoprolol Use in Hypertensive Pregnancy Disorder – a Single-center Study

Hypertensive pregnancy disorder is among the leading causes of maternal and fetal mortality, affecting 5–7% of pregnant women. Beta-blockers are known to improve endothelial dysfunction and may be beneficial in the treatment of this condition. We carried out a retrospective observational study involving 80 pregnant women with hypertension, admitted to the Alexandru Simionescu County Hospital, Hunedoara, Romania, from May 1, 2021 to December 31, 2023. Systolic blood pressure, diastolic blood pressure, and hypertension treatment were compared between patients receiving metoprolol and patients receiving other antihypertensive medication. Preeclampsia and premature delivery occurred in a significantly higher proportion among those who received other antihypertensive medication (p = 0.006 and p = 0.021, respectively). Low Apgar score (Apgar 6) was encountered in 2.5% of cases. Intrauterine growth restriction did not occur in either study group, and the neonatal and maternal mortality rates were zero in both groups. Metoprolol had demonstrated its benefits in treating hypertensive pregnancy disorders. The final goal is improving maternal and fetal outcomes.